The RNA-binding motif (RRM) gene on Y chromosome (RBMY), encoding a male germ cell-specific RNAbinding protein associated with spermatogenesis, was found inserted by hepatitis B virus (HBV) DNA in one childhood hepatocellular carcinoma (HCC). This study is aimed to explore the oncogenic potential of the RBMY protein. The RBMY transcripts, expressed exclusively in the testis of normal people, were detected by reverse transcription-polymerase chain reaction in 36% of HCCs from 90 males and in 67% of hepatoblastoma from six boys. The nontumor liver counter parts, cirrhotic liver tissues from children with biliary atresia, and other types of cancers, such as bile duct, colon, stomach, lung, prostate, and kidney, were all negative for RBMY expression. One to four types of RBMY transcripts, including wild type and variants with N-terminal RRM deletion, C-terminal SRGY (serine-arginine-glycine-tyrosine) boxes deletion, or deletion of both domains, were found in the testis and liver cancer tissues. The wild-type RBMY protein was expressed in the nucleus and demonstrated its tumorigenicity by transformation of mouse fibroblast NIH3T3 cells and in vivo tumor formation. The RBMY variant protein with deletion of C-terminal exons 9-12 was trapped in the cytoplasm and showed decreased tumorigenicity. Our results suggest that RBMY is a new candidate oncogene specific for male liver cancer.
Introduction
The RBMY (RNA-binding motif (RRM), Y chromosome; formerly RBM or YRRM) gene is found on the Y chromosome of all mammals and its microdeletion is associated with male infertility (Ma et al., 1993; . At least 30 copies of RBMY genes and pseudogenes are located on both arms of the Y chromosome, but only a few are functional (Chai et al., 1997; Elliott et al., 1997) . These genes encode RNA-binding proteins with N-terminal RRMs and a C-terminal auxiliary domain containing four repetitive segments with a high proportion of serine, arginine, glycine, and tyrosine residues (SRGY boxes) (Chai et al., 1998) . It has been reported that RBMY has a homologue, RBMX (formerly heterogeneous nuclear ribonucleoprotein G, hnRNP G), located on the human X chromosome with only one copy of the SRGY box (Lingenfelter et al., 2001) . In contrast to the ubiquitous presence of RBMX, expression of human RBMY is confined to the nuclei of human germ cells between the spermatogonial and round spermatid stages (Elliott et al., 1997 (Elliott et al., , 1998 . In men, the functional copies of RBMY are located at the AZFb (azoospermia factor) region of Y chromosome long arm (Najmabadi et al., 1996; Nakahori et al., 1996) . Germ cells with deletion of the AZFb locus are arrested at the meiotic stage of spermatogenesis (Vogt et al., 1996) , with reduced or abolished expression of RBMY (Elliott et al., 1997) . Several proteins involved in pre-mRNA splicing or RNA metabolism have been identified to interact with RBMY in the testis by yeast two-hybrid screens, such as SR proteins and STAR proteins (Venables et al., , 2000 Elliott et al., 2000) . Although the exact function of RBMY protein is unclear, it may act as a tissue-specific RNA processing factor that functions in conjunction with SR and STAR proteins to direct splicing in germ cell nucleus.
Hepatocellular carcinoma (HCC) and hepatoblastoma (HB) are two major types of human liver cancer. HCC is one of the most common cancers worldwide and a leading cause of cancer death in Taiwan (Lin et al., 1977) . The most important risk factor for HCC is chronic infection by the hepatitis B virus (HBV), which was found in around 80% of adult HCC and nearly 100% of childhood HCC (Chen et al., 1986; Chang et al., 1989) . Other etiological agents for adult HCC include hepatitis C virus (HCV) infection, exposure to aflatoxins, and excessive intake of alcohol (Montesano et al., 1997; Idilman et al., 1998) . HCC is more common in men than women, with a sex ratio ranging from 3 : 1 to 6 : 1. The reasons for the male predominance and the oncogenic pathways leading to malignant transformation of liver cells remain obscure. HBV and HCV are considered to have no or weak transforming abilities; therefore, genetic aberrations of the host cell may play a more direct role in the carcinogenesis process. Genetic studies show chromosomal abnormalities in HCC, such as HBV DNA integrations and mutations, deletions, amplifications, and translocations of cellular DNA (Buendia, 2000; Bre´chot et al., 2000) . Identification of candidate oncogenes and tumor suppressors in the most frequently altered chromosomal regions may help to clarify the oncogenic mechanisms.
HB is an embryonal liver tumor that arises from normal, noncirrhotic liver. Infections with HBV and HCV do not seem to play a role in its etiology. The pathogenesis of HB is therefore thought to be different from that of HCC. It has been shown that the incidence of HB is elevated in patients with Beckwith-Wiedemann syndrome (Byrne et al., 1993) or familial adenomatous polyposis (Iwama and Mishima, 1994) . Genetic abnormalities including the loss of heterozygosity of chromosome arm 11p, isochromosome 8q, and trisomies 2 and 20 have been found in HBs (Ding et al., 1994) . The molecular pathogenesis of HB is still poorly understood.
In our previous report, HBV DNA integration at intron 6 of RBMY gene was identified in one childhood HCC tissue (Tsuei et al., 2002) . We also found that the expression of RBMY transcripts was detected in the corresponding tumor and three other childhood HCC tissues. To further characterize the possible oncogenic role of RBMY, this study is aimed to elucidate the expression rate of RBMY in liver tumors and various other types of cancer, and the transforming ability of the RBMY protein.
Results
Reverse transcription-polymerase chain reaction (RT-PCR) detection of RBMY transcripts in paired tumor and nontumor tissues Paired tumors and nontumor tissues obtained from patients with liver cancers or other types of tumors were analysed by RT-PCR using primer pair S specific to the exons 2 and 5 of RBMY gene. The location of primer pair S is shown in Figure 1 . The human porphobilinogen deaminase (PBGD) transcripts were also amplified as an internal control. A 473-bp cDNA fragment could be amplified only from RBMY-expressing tissues, while a 273-bp PBGD control band was amplified from all tissues. The results are presented in Figure 2 and summarized in Table 1 . The RBMY transcripts were detected only in liver tumors (HCC and HB), but not in the other six types of tumors, including cholangiocarcinoma, carcinomas of the colon, kidney, lung, stomach, and prostate. The amplification of internal control PBGD cDNA confirmed that the absence of the RBMY band represented an actual negative expression of RBMY transcripts. RBMY transcripts were detected in the tumor parts of one-to two-thirds of liver cancers from male patients, but not in any of the other six types of cancers. None of the cirrhotic livers of biliary atresia (BA), nontumor parts of HCC, or HB-bearing livers were positive for RBMY expression. The RBMY transcripts was detected in 32 (36%) out of 90 HCCs taken from 13 boys and 77 male patients, regardless of HBV and HCV status, and in four (67%) of six boys with HB (Table 1 ). In contrast, the RBMY mRNA expression was not detected in any of the 22 HCCs and two HBs taken from girls and female adults. Besides, the RBMY transcripts was not detected in any of the seven cirrhotic liver tissues of BA, and 67 other tumor tissues, including cholangiocarcinoma, and carcinomas of the colon, kidney, lung, stomach, and prostate (Table 1) .
Patterns of RBMY transcripts in the testis and liver cancer
To characterize the RBMY transcripts in liver cell cancers, tissues from two cases of non-B-and non-Crelated adult HCCs, two HBV-related and two HCVrelated adult HCCs, three childhood HCCs, and one HB with sufficient amount of RNA were chosen for further analyses. The poly(A) RNA from the testis was used for comparison. The RBMY cDNA fragments encompassing exons 2-12 were amplified by RT-PCR using primer pair L. The location of primer pair L on the RBMY gene is shown in Figure 1 . We classified the RBMY transcripts obtained from the testis and liver cancers into four types according to the presence of N-terminal RNA recognition motif (RRM) and C-terminal SRGY boxes ( Table 2 ). The full-length, intact RBMY cDNA was classified as type A transcripts, which were detected in nine of the 10 liver cancers. Type B transcripts were the variants with less than four copies of SRGY boxes. In one HB tissue, only type B transcripts losing the fourth SRGY box due to exon 10 deletions were identified. Type C variants had a deletion of exon 4 with the loss of the RRM, which created a frame shift thereafter. Type D variants had deletions on both RNAbinding domain (exon 4) and SRGY boxes, which theoretically will disrupt the function of RBMY. The results indicate that wild-type and type B variants are the most common transcripts of RBMY expressed in the testis and liver cancers.
Overexpression of RBMY in NIH3T3 cells confers transformation properties
The wild-type RBMY is composed of 496 amino acids and its organization is shown in Figure 1 . The cDNA fragments (around 1.5 kb) containing the entire coding region of RBMY were amplified from the HCC 1 tissue, from which the intron 6 of the RBMY gene was first identified with HBV integration and cloned into expression vector pcDNA3 and transfected into mouse fibroblast NIH3T3 cells. The recombinant clone pcDNA3-RBM496 encoded the wild-type RBMY protein fused with three copies of nine-amino-acid HA tags. Another clone pcDNA3-RBM384 contained one base 
Human testis poly(A) RNA was purchased from Clontech, Inc. (Palo Alto, CA, USA). HCC, hepatocellular carcinoma; HB, hepatoblastoma; NA, not available. HCC1, 2, and 3 were from HBV-related HCC children, 4 and 5 were HCV-related HCC adults, 6 and 7 were HBV-related HCC adults, and 8 and 9 were non-B/C-related HCC adults deletion at the end of exon 8 (amino acid 300), which created a frame shift and encoded a C-terminal (exons 9-12) deletion protein. By immunofluoresence assay using anti-HA antibodies, the HA-tagged RBM496 protein was located in the nucleus (Figure 3a and b) . On the other hand, the location of HA tag-RBM384 fusion protein shifted to the cytoplasm (Figure 3c and d). The results indicated that the C-terminal sequence encoded by exons 9-12 contributed to the nuclear localization ability of RBMY protein. Figure 3b ). The RBMY variant protein of around 46 kDa was not detected by the anti-SRGY antibodies in the RBM384-transfected cell extracts ( Figure 3B ), which might be attributed to the loss of two copies of SRGY boxes in the RBM384 variant. The results of Northern blot assay demonstrated that the RBMY transcripts of around 1.5 kb were expressed in both the wild-type RBM496-and the variant RBM384-transfected cells ( Figure 3C ). The properties of transfected cells were characterized by growth under low serum (0.5%) condition, soft agar assay, and nude mice inoculation. The results are summarized in Table 3 . The pcDNA3-RBM496-transfected cells proliferated under low serum condition and aggregated to form colonies in soft agar. The cell numbers of pcDNA3-RBM384 transfectants in low serum medium and soft agar reduced 50-80% as compared to the wild-type RBM496 expression cells. The NIH3T3 cells or the vector DNA-transfected NIH3T3 cells grew poorly in both the low serum medium and soft agar.
The tumorigenicity of RBMY was further examined by the injection of low dose (10 6 cells) or high dose (5 Â 10 6 cells) of transfected (or parental) cells into nude mice. The results are summarized in Table 4 . Both low and high doses of wild-type RBMY (pcDNA3-RBM496) transfectants induced tumor formation in nude mice. The tumorigenicity of the high doses of type B variant RBMY (pcDNA3-RBM384)-transfected cells were similar to the wild-type RBMY, while the low-dose injection failed to induce tumor formation in nude mice. These results indicate that RBMY possesses the oncogenic potential and its C-terminal sequence is essential for both the nuclear localization and transformation functions.
Discussion
Altered expressions of tumor-associated genes have been observed in primary liver cell cancers, such as activation of c-myc (Peng et al., 1993) , cyclin D1 (Nishida et al., 1994) or b-catenin genes (Miyoshi et al., 1998) , and inactivation of tumor suppressor functions of p53 or RB genes (Lin et al., 1996) . Such up-or downregulations of tumor-associated genes are, however, neither gender specific nor liver tumor specific. In this study, we demonstrated that the RBMY gene was activated specifically in liver cell cancers of male patients. The prevalence rate was around 36% in male HCCs and 67% in HBs taken from male patients. The cirrhotic livers of BA, the nontumor parts of HCC-or HB-bearing livers, and tissues from female patients were all negative for RBMY expression. Although the sample sizes of cancers from other anatomic sites in this study were small, RBMY transcripts were not detected in tumors other than liver cancers. The high expression rate and specificity to liver cell cancers suggest a strong association of RBMY with hepatocarcinogenesis. The transfection experiments showed that wild-type RBMY protein was expressed in the nuclei and transformed fibroblast NIH3T3 cells, while the C-terminal (exons 9-12) deletion protein was trapped in the cytoplasm with a dose-dependent tumorigenicity. Our results suggest that RBMY, a male germ cell-specific RNA-binding protein, is a new oncogene candidate for male liver tumor.
The high incidence of primary liver tumors in male compared to female has been reported in previous studies (Exelby et al., 1975; Flickinger et al., 1997) . In Taiwan, the male-female ratio of HCC is around 4.5 : 1 and of HB around 2.9 : 1 (Chen et al., 1988; Ni et al., 1991; Lee and Ko, 1998) . The detailed mechanisms of male predominance in primary liver tumors so far remain unclear. Our studies reveal that the RBMY gene possesses the oncogenic potential and is expressed in more than one-third of male liver cancers. Although RBMY was firstly identified with HBV integration in childhood HCC, other viral and cellular factors in addition to HBV integration are possibly related to the activation of RBMY in liver cells. Our findings provide a new model for studying the association of RBMY and possibly other Y chromosome-specific genes with the male predominance of liver cancers.
RBMY protein is expressed in the nuclei of male germ cells. The RRM, encoded by exons 2-4 of the RBMY gene, is an ancient motif found in the RNA-binding proteins of prokaryotes and eukaryotes. Nuclear RNAbinding proteins may regulate gene expression at the post-transcriptional level by the involvement in regulations of pre-mRNA splicing, mRNA stability, and the transport of RNA between the nucleus and cytoplasm (Nagai et al., 1995) . The native RNA target and function of RBMY are still not yet known. In the testis, the interacting partners of RBMY detected by the twohybrid approach are also found to be RNA-binding proteins and fall into three major groups: SR of SRrelated proteins, the hnRNP G-related proteins, and the STAR proteins (Venables et al., , 2000 Elliott et al., 2000) . SR proteins are a family of proteins with arginine-and serine-rich domains, and are known to be important in the regulation of splicing during cell differentiation and development (Valca´rcel and Green, 1996) . STAR is a subfamily of the KH (hn RNP K homology) domain containing RNA-binding proteins involved in the signal transduction and activation of RNA (Vernet and Artzt, 1997) . The interaction of RBMY with these splicing-associated proteins implies that RBMY may function as a tissue-specific regulator of pre-mRNA splicing. It has been reported that many cancer-associated genes, such as Bax, Fas, and caspase-2, produce alternatively or aberrantly spliced variants with opposing function (Mercatante and Kole, 2000) . In a number of cancers, the ratio of the spliced variants is frequently shifted so that the antiapoptotic splice variant predominates (Jiang and Wu, 1999; Kume Colonies greater than 100 mM in diameter were counted 4 weeks after plating the cells in 0.4% agarose. The colony number is based on four independent experiments. c The variant type RBMY loses two of the four copies of SRGY boxes due to one base deletion at the end of exon 8. RBM384 was a variant type RBMY losing two of the four copies of SRGY boxes due to one base deletion at the end of exon 8 et al., 1999). The issue of whether the activation of RBMY in liver cells may change the expression patterns of certain genes through alternative splicing and lead to tumor formation needs to be clarified by further studies.
The RBMY transcripts have been reported to contain at least six subfamilies (RBMI to RBMVI) in the testis, and only RBMI is actively transcribed and encodes functional protein (Chai et al., 1997) . In this study, we simplify the classification of RBMY transcripts to four types according to the integrity (type A), deletions at SRGY boxes (type B) or RRM domain (type C), or at both domains (type D). Types C and D transcripts possibly are products of RBMY pseudogenes since they lose RNA-binding function and possess frame shifts and preterminations. Types A and B transcripts are the most conserved expression patterns in the testis and liver tumor tissues. Type B transcripts contain a group of products with deletions of different numbers of SRGY boxes. The SRGY boxes have been proved to be essential for protein-protein interaction and two copies of SRGY boxes are capable of interacting with the STAR proteins (Venables et al., , 2000 . In one HB tissue, type B variants having three copies of SRGY boxes (encoded by exons 7-9) are uniquely expressed and possibly still maintain the transformation ability. Transfection and transformation assays showed that RBM384, a variant type RBMY, possessed two copies of SRGY boxes but lost the C-terminal sequences encoded by exons 9-12, shifted its cell localization to the cytoplasm and retained partial transformation activity. We suggest that SRGY boxes and the C-terminal sequence may affect protein interaction and cell localization of the RBMY protein, and both of which seem to be essential for the transformation activity.
This study firstly reports that RBMY, a candidate gene for male infertility, possesses the oncogenic potential and is activated in more than one-third of male liver cancers. The role of RBMY in liver carcinogenesis, the mechanism and function of RBMY activation are questions waiting to be answered in the near future.
Materials and methods

Tissues
The paired tumor and nontumor tissues were from 14 children (13 males and one female, 3.5-14 years of age) with primary HCC, eight children (six males and two females, 9 months to 3.5 years of age) with HB, 98 adult patients (77 males and 21 females, 17-85 years of age) with primary HCC, eight patients (four males and four females, 31-71 years of age) with cholangiocarcinoma, 14 patients (11 males and three females, 49-90 years of age) with colon cancer, 10 patients (nine males and one female, 36-85 years of age) with renal cancer, 10 patients (all males, 37-74 years of age) with lung cancer, and 15 patients (14 males and one female, 44-78 years of age) with stomach cancer. Tumor tissues from five patients (all males, 71-87 years of age) with prostate cancer, nontumor prostate tissues from five patients (all males, 52-79 years of age) with nodular hyperplasia, and cirrhotic liver tissues from seven children (all males, 1 month to 1 year of age) with BA were also studied. Of the 98 adult HCC patients, 53 were HBVrelated cases, 26 were HCV-related, and 19 were non-HBV/ HCV-related cases.
Cell culture and transfection NIH3T3 cells (National Health Research Institute, Taiwan) were grown in Dulbecco's modified Eagle's medium supplemented with 10% calf serum (HyClone). Transfections were performed using Lipofectamine (Invitrogen/Life Technologies) according to the manufacturer's protocol. Transfectants were selected with 0.6 mg/ml geneticin-(G418, Invitrogen/Life Technologies) supplemented growth medium.
RT-PCR
Total RNA was extracted using TriReagent (Molecular Research Center, Inc.) according to the manufacturer's protocol. The structural integrity of the isolated RNA was confirmed by electrophoresis of the RNA through a 1.2% gel. RNA obtained from hepatoma cell line HuH-7 was used as a positive control. In all, 5 mg of the total RNA were converted to first-strand cDNA using the Preamp cDNA synthesis kit (Invitrogen/Life Technologies). PCR was performed using 4 ml of the synthesized cDNA template with 0.2 mmol/l deoxynucleoside mix, 1 Â PCR buffer, 2 U Taq polymerase (Biotools), and 0.2 mmol/l primers in a 50 ml reaction volume. Two sets of primer pairs were used for the amplification of target RBMY and internal control human PBGD transcripts, respectively. The short primer pair (S) were designed from exons 2 and 5 of the RBMY gene (shown in Figure 1 ): forward 5 0 -GAAAC CAATGAGAAGATGCTT-3 0 and reverse 5 0 -TTGCTTCTT GCCACAGCAG-3 0 . Primer sequences for internal control PBGD transcripts were: forward 5 0 -TGTCTGGTAACGGC AATCCGGCT-3 0 and reverse 5 0 -GGTCCACTTCATTCTT CTCCAGG-3 0 .
Plasmids
The entire coding region of RBMY was obtained from childhood HCC or HB tissues by RT-PCR amplification using a long primer pair L (shown in Figure 1 ). The sequences are: forward primer 5 0 -ATGGTAGAAGCAGATCATCCT-3 0 and a reverse primer 5 0 -TGCTTTAATATCTGCTCGA-3 0 . The PCR products were cloned into pDONR201 vector (Invitrogen/Life Technologies) for sequencing analysis (automated sequencer, Model 377, Applied Biosystem, Foster City, CA, USA) or into a modified pcDNA3 vector (with three copies of HA tag, a gift from Dr LM Huang) for mammalian cell expression.
Immunofluorescence assay
Cells were plated onto four-chamber slides (Nalgen Nunc, Inc.) at a density of 2 Â 10 4 cell per well and cultured overnight. At 24 h after transfection, chamber slides were rinsed with phosphate-buffered saline, fixed with acetone, and stained with 1 : 1750 diluted anti-HA monoclonal antibodies (Convance) followed by goat anti-mouse IgG conjugated to FITC (Santa Cruz Biotechnology). Coverslips were mounted on slides with fluorescent mounting medium (Dako Cytomation) for microscopic examination.
Antibodies and Western blot analysis
The antibodies against the SRGY box region of RBMY were prepared as the same method described previously (Elliot et al., 1998). In brief, the four copies of SRGY boxes were PCR amplified from the intact form RBMY cDNA using primers 5 0 -AAAAAAACTCGAGGCTGTGGCAAGAAGCAATAGT and 5 0 -AAAAAAAGGTACCATGATTTCTATATCCTCTA-GA. The PCR products was cut with XhoI and KpnI (restriction sites underlined), ligated into vector pRSETA (Invitrogen/Life Technologies), and transformed into Escherichia coli BL21 cells. The polypeptide of around 28 kDa was purified and injected into a rabbit. Monoclonal anti-b-actin antibodies were purchased from Sigma.
Cells were resuspended in cold RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% NP40, 0.1% SDS, 100 mM AEBSF, 0.08 mM aprotinin, 2.2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin, 1.4 mM E-64), and centrifuged at 12 000 r.p.m. for 10 min at 41C. Equal amounts (50 mg) of protein extracts were resolved by 10% SDS-polyacrylamide gel and transferred onto a polyvinylidine difluoride (PVDF) membrane (Millipore). The blots were incubated with polyclonal anti-SRGY antibodies at a 1 : 5000 dilution. For detection, horseradish peroxidase-conjugated goat anti-rabbit antibodies were used, followed by the enhanced chemiluminescence system (Pierce Biotech, Inc.).
RNA analysis
Total cellular RNA was prepared by a guanidinium isothiocyanate/acid phenol method. For Northern analysis, RNA samples (20 mg) were resolved by electrophoresis through 1% agarose gel in 2.2 M formaldehyde and blotted onto an Immobilon-N membrane (Millipore). The 32 P-labeled hybridization probe was made by PCR amplification of a 1.5 kb cDNA fragment containing the entire coding region of RBMY. The b-actin cDNA was purchased from BD Biosciences (Clontech) and labeled using the Rediprime II labeling system (Amersham Biosciences).
Soft agar and tumorigenicity assays
Soft agar assays were performed in 60 mm dishes by plating 5 Â 10 4 cells in the growth medium with 0.4% agarose on a 0.7% agarose base. After incubation for 4 weeks, colonies were stained with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (5 mg/ml; Sigma) at 371C for 2 h. Colonies larger than 100 mm were counted for each plate. Tumorigenicity was assayed by the injection of 10 6 and 5 Â 10 6 cells into athymic nude mice (BALB/c-Hfhll nu/nu, 6-8 weeks of age) subcutaneously (s.c.) on one side at the right flank. The mice were examined weekly and killed 2 months later. The volume of a tumor was calculated from its dimensions (length Â width 2 )/2, assuming a hemiellipsoid shape (Geran et al., 1972) . Nude mice were purchased from the National Laboratory Animal Breeding and Research Center (National Science Council, Taiwan) and kept under pathogen-free conditions. The study protocol was approved by the Animal Care Committee of National Taiwan University College of Medicine.
